Mehmet Eltan

Mehmet Eltan

Auto-generated profile, based on publicly available information

Mehmet Eltan

Department of Pediatric Endocrinology and Diabetes, Marmara University, School of Medicine , Istanbul 34854

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MEMehmet Eltan
Mehmet Eltan
CACeren Alavanda
Ceren Alavanda
ZAZehra Yavas Abali
Zehra Yavas Abali
BTBusra Gurpinar Tosun
Busra Gurpinar Tosun
IKIlknur Kurt
Ilknur Kurt
STSerap Turan
Serap Turan
Context: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole. Objective: This work aimed to identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups. Methods: Fifty patients (24 males) from 39 unrelated families were included. Based on initial evaluation, PHEX gene sequencing was performed in patients with clinical and biochemical findings suggestive of FGF23-dependent HH. If sequencing showed no alterations, multiplex ligation-dependent probe amplification (MLPA) analysis for PHEX was conducted. Initially, a specific gene panel was performed for FGF23-independent HH or those in whom the PHEX gene showed no genetic alteration. Results: Genetic etiology was revealed in 43 patients from 33 families. PHEX gene variants (4 novel) were identified in 24 patients from 19 unrelated families (50%). SLC34A3 was the second most common (16.6%) and the rest were rarer causes of hypophosphatemia (DMP1 n = 3, SLC34A1 n = 2, CLCN5 n = 2, OCRL n = 2, FAM20C n = 1, SLC2A2 n = 1). When the genetically proven FGF23-dependent (n = 28) and FGF23-independent (n = 15) HH groups were compared for clinical and biochemical features; lower phosphate and TmP/GFR SDSs and higher ALP SDS with more severe clinical rickets were detected in FGF23-dependent group, whereas higher serum and urine calcium and lower PTH levels were detected in FGF23-independent group. Conclusion: The application of MLPA provided an additional explanatory value of 10% to the molecular etiology. However, 10% of the cases of HH still remain unexplained even after a comprehensive genetic work-up. Biochemical findings suggest distinct biochemical profiles between FGF23-dependent and FGF23-independent HH groups.

8 August 2024 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
CACeren Alavanda
Ceren Alavanda
ŞDŞenol Demir
Şenol Demir
SGSerçin Güven
Serçin Güven
MEMehmet Eltan
Mehmet Eltan
SESevgi Bilgiç Eltan
Sevgi Bilgiç Eltan
STSerap Turan
Serap Turan
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.

4 February 2026 in European Journal of Endocrinology
Verified
Journal Article
Closed access
MEMehmet Eltan
Mehmet Eltan
ZAZehra Yavas Abali
Zehra Yavas Abali
ACAylin Tugba Canbaz
Aylin Tugba Canbaz
TKTarik Kirkgoz
Tarik Kirkgoz
SKSare Betul Kaygusuz
Sare Betul Kaygusuz
TGTulay Guran
Tulay Guran
Background: Premature pubarche (PP) is characterized by the early onset of pubic or axillary hair, body odor, or mild acne, most commonly reflected by elevated plasma dehydroepiandrosterone-sulfate (DHEA-S) concentrations. However, recent evidence suggests that 11-oxygenated adrenal androgens [11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT)] may better represent true androgenic activity. Aim: This study aims to evaluate the predictive value of adrenal androgens in determining growth characteristics among girls with PP. Subjects and Methods: A prospective study was conducted to evaluate anthropometric and clinical features and to quantify plasma adrenal androgens—including DHEA, DHEA-S, androstenedione (A4), androsterone, 11OHA4, and 11OHT—using liquid chromatography-mass spectrometry in 53 girls with isolated PP at presentation and during follow-up. Thirty-six age-matched girls without PP served as the control group. Results: The height, body mass index-standard deviation score (SDS), DHEA, DHEA-S, A4, androsterone, and 17OH-pregnenolone concentrations were higher (P < .0001), whereas no difference in 11OHA4 and 11OHT concentrations was observed in the PP group compared with controls. There was no correlation of adrenal androgen concentrations with height, corrected height, and growth velocity at baseline or during follow-up of 2.7 years. Corrected height SDS was positively correlated with baseline corrected height SDS (r = .63, P < .0001), baseline bone age (BA)/chronological age ratio (r = .31, P = .02), and baseline BA SDS (r = .32, P = .01) but not with hormone concentrations. Conclusion: Isolated idiopathic PP appears to be a benign variant of normal development. In this setting, adrenal androgen concentrations are not associated with adverse linear growth outcomes and are unlikely to influence clinical management, supporting a conservative approach after exclusion of pathological causes.

16 January 2026 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
ITihsan turan
ihsan turan
MAMuge Atar
Muge Atar
MEMehmet Eltan
Mehmet Eltan
AAAhmet Anık
Ahmet Anık
EBEda Celebi Bitkin
Eda Celebi Bitkin
ATAli Kemal Topaloglu
Ali Kemal Topaloglu
Pathogenic variants in the SLC34A1 gene, which encodes the sodium-phosphate cotransporter NaPi-IIa, lead to a spectrum of renal tubular disorders, including infantile hypercalcemia type 2, nephrolithiasis/osteoporosis-hypophosphatemia type 2, and Fanconi renotubular syndrome type 2. Despite increasing recognition of SLC34A1 -related disorders, data on genotype–phenotype correlations and treatment response remain limited due to the rarity of the condition. We retrospectively analyzed the clinical, biochemical, and molecular features of 11 patients from unrelated families carrying 12 pathogenic or likely pathogenic SLC34A1 variants, three of which were novel. Next-generation sequencing and ACMG-AMP criteria were used for variant classification. Biochemical parameters including serum phosphate, calcium, parathyroid hormone, urinary calcium, and TmP/GFR were evaluated. Treatment response to oral phosphate supplementation was longitudinally assessed. All patients exhibited hypercalciuria and nephrocalcinosis at diagnosis. Oral phosphate supplementation (5–20 mg/kg/day) resulted in normalization of urinary calcium excretion in 10 of 11 cases, regardless of baseline serum phosphate status. Linear growth improved in all but one patient. The identified mutations clustered primarily within functional domains of the NaPi-IIa protein, particularly amino acid residues 109–205 and 375–487. Several splice-site and codon-specific variants—such as those affecting Gly153 and Gly194—were highlighted as potential pathogenic hotspots. Our findings expand the mutational and phenotypic spectrum of SLC34A1 -related disease and reinforce the utility of oral phosphate supplementation in managing hypercalciuria and promoting growth. Functional domain mapping and variant clustering analyses enhance understanding of disease mechanisms and support the importance of early diagnosis and long-term surveillance.

7 November 2026 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
HKHülya Kahraman
Hülya Kahraman
DDDurmus Durmaz
Durmus Durmaz
AGAylin Gunay
Aylin Gunay
MEMehmet Eltan
Mehmet Eltan
TGTulay Guran
Tulay Guran
Background: Isolated hyperchlorhidrosis (HYCHL; OMIM 143860) is caused by biallelic CA12 variants encoding carbonic anhydrase XII (CA XII), a transmembrane enzyme that mediates sodium and chloride reabsorption in sweat glands, leading to excessive salt loss. Clinically, HYCHL presents in infancy with recurrent hyponatremic dehydration secondary to excessive salt loss, often mimicking pseudohypoaldosteronism (PHA) or cystic fibrosis (CF). Case Presentation: A 5-month-old girl presented with irritability, lethargy, poor feeding, severe hyponatremia (110 mEq/L), and hyperkalemia (7.1 mEq/L). Congenital adrenal hyperplasia was excluded by endocrine evaluation. Markedly elevated plasma renin activity and aldosterone initially suggested PHA; however, low urinary sodium excretion during hyponatremia indicated an extrarenal source of salt loss. Three further episodes occurred, predominantly during summer. Although the parents consistently reported a salty taste of the infant’s skin. Clinical exome sequencing identified two unreported compound heterozygous CA12 missense variants, c.823C>T p.(Arg275Trp) and c.694C>A p.(Pro232Thr), with parental testing confirming trans inheritance. No pathogenic variants were detected in CFTR or PHA-associated genes. By 19 months of age, the patient had remained free of hyponatremic episodes for nine months without disease-specific treatment, with normal growth and neurodevelopment. Conclusion: This case expands the mutational spectrum of isolated hyperchlorhidrosis by identifying two unreported variants in CA12 and highlights the importance of considering isolated hyperchlorhidrosis in infants with recurrent salt-wasting when routine evaluation does not support PHA or CF.

15 December 2022 in Trends in Pediatrics
Verified
Journal Article
Closed access
SESevgi Bilgiç Eltan
Sevgi Bilgiç Eltan
AAArzu Akçay
Arzu Akçay
EBElvan Bayramoğlu
Elvan Bayramoğlu
MEMehmet Eltan
Mehmet Eltan
TATeoman Akçay
Teoman Akçay
GAGönul Aydoğan
Gönul Aydoğan